Phase 3 N=1,794 Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'
Influenza
Primary: Rate of Healthy Adults Aged ≥19 Years With Seroconversion — 47.7; 49.5; 49.0; 78.7 percentage of subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=2,102 A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris
Acne Vulgaris
Primary: Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS) — 29.9; 21.2 Percentage of Patients
Phase 3 N=34 Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors
Hemophilia A With Inhibitors
Primary: Number of Bleeds During 6 Month Treatment Period — 13.1; 5.0 bleeds — p=<0.001
Phase 3 N=241 Dysport® Pediatric Lower Limb Spasticity Study
Cerebral Palsy · Muscle Spasticity · Children
Primary: Change in MAS Score in the Gastrocnemius-soleus Complex (GSC) at the Ankle Joint of the (Most) Affected Lower Limb — -0.86; -0.97; -0.48 units on a scale — p=0.0029
N/A N=300 Simplified Anti-Thrombotic Therapy for FFR
Coronary Artery Disease
Primary: Thrombotic Complications — 0; 0; 0 Number of Patients — p=1
Phase 2 N=180 Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults
Tuberculosis
Primary: Number of Subjects With Solicited Local Symptoms — 8; 3; 35; 33 Subjects
Phase 4 N=109 Effect of Deep Neuromuscular Block on Surgical Conditions in Morbidly Obese Patients
Surgical Conditions
Primary: Surgical Rating — 4.2; 4.8 units on a scale — p=0.001
N/A N=6 Using Attentional Bias Modification to Address Trauma Symptoms
Posttraumatic Stress Disorder
Primary: Clinician-Administered PTSD Scale (CAPS-5) — 10.3; 10.0 units on a scale
N/A N=12 The Fasting II Study
Diabetes · Metabolic Diseases
Primary: Difference in Mean Glucose Level Between Baseline and the End of the Sixth Week. — 104.7; 104.5 mg/dL
Phase 3 N=155 Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm
Spasticity of the Upper and Lower Limb Due to Cerebral Causes
Primary: Occurrence of Treatment-Emergent Adverse Events (AEs), AEs of Special Interest (AESIs), and Serious AEs (SAEs) by Injection Cycle, Overall and Related to the…
N/A N=64 A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Mean Change in Severity of Morning Stiffness (Using 100mm VAS) From Baseline (Week 0) to Final Follow-Up Visit — -5.2 units on a scale
Phase 3 N=47 Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL
Acute Lymphoblastic Leukemia (ALL)
Primary: Number of Participants With Adverse Event to HD-MTX Treatment in NOPHO ALL-2008 as a Measure of Toxic Mtx Concentrations in Blood, Nephrotoxicity, Hepatotoxicity…
Phase 1 N=15 Study of IMC-11F8 in Participants With Advanced Solid Tumors
Neoplasms
Primary: Number of Participants With 1 or More Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) — 3; 6; 6; 1 participants
N/A N=60 Hemodynamic Comparison of Tissue Aortic Valves
Aortic Valve Stenosis
Primary: Aortic Valve Mean Gradient (mm Hg) at Peak Exercise — 11; 14; 11 mm Hg
Phase 2 N=19 Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma
Bile Duct Cancer · Intrahepatic Cholangiocarcinoma · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Median Progression Free Survival (PFS) — 1.8 months